An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes

Type 1 diabetes (T1DM) is a chronic autoimmune disease that leads to destruction of insulin producing beta cells, which leaves the patient dependent on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in T1DM, but interventions to prevent clinical progression before T1DM onset are not yet available.